Research programme: Alzheimer's disease diagnostics - Axonyx/University of Melbourne

Drug Profile

Research programme: Alzheimer's disease diagnostics - Axonyx/University of Melbourne

Latest Information Update: 24 Jan 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Melbourne
  • Class Cholinesterases; Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jan 2003 Discontinued - Preclinical for Alzheimer's disease (diagnosis) in Australia (unspecified route)
  • 17 Jan 2003 Axonyx has decided to out-license or cancel its diagnostic programme for Alzheimer's disease
  • 17 May 2000 Preclinical development for Alzheimer's disease (diagnosis) in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top